ZIRABEV is a biosimilar to the original biologic medication, Avastin (bevacizumab), and is designed to inhibit the growth of blood vessels that supply tumors with oxygen and nutrients, a process known as angiogenesis. By blocking the vascular endothelial growth factor (VEGF) pathway, ZIRABEV helps to slow the progression of cancer by starving tumors of the necessary components they need to grow and spread. It is used in the treatment of various types of cancer, including colorectal, lung, glioblastoma, kidney, and cervical cancers among others. As a biosimilar, ZIRABEV has been shown to have no clinically meaningful differences in terms of safety, purity, and potency when compared to its reference product, Avastin, offering a potentially more cost-effective option for patients requiring this type of targeted therapy.